Ionis Pharmaceuticals Shows Strong Guru Model Rating

Ionis Pharmaceuticals is highlighted in a report for achieving a 66% rating using a growth investment model. The stock’s favorable characteristics, including a solid book-to-market ratio and return on assets, suggest potential for future growth despite some weaknesses.

Date: 30-10-2024

AI Rating: 6

The report discusses Ionis Pharmaceuticals Inc's performance according to a specific growth investment strategy developed by Partha Mohanram. The stock has received a rating of 66%, indicating it possesses several characteristics deemed favorable for growth.

Key Indicators:

Book/Market Ratio: The stock has passed this criteria, suggesting it is trading at a favorable valuation relative to its book value.
Return on Assets: This indicator is green, showing the company effectively generates profit from its assets.
Cash Flow from Operations to Assets: This has been marked as a pass, indicating good operational efficiency.
Cash Flow from Operations to Assets vs. Return on Assets: This criterion has failed, which might indicate some inconsistency in the operational cash flow relative to asset returns.
Return on Assets Variance: This is another positive indicator, suggesting stability in earning returns on assets.
Sales Variance: The stock has passed this test, indicating solid sales performance.
Advertising to Assets, Capital Expenditures to Assets: Both of these criteria have failed, suggesting that advertising or capital spending may be less effective relative to the company's asset base.
Research and Development to Assets: This pass indicates the company is actively investing in innovation.

Overall, while Ionis Pharmaceuticals has shown a solid performance in most critical indicators like book-to-market ratio and return on assets, the failed metrics in operational cash flow and expenditure indicate areas that might require closer scrutiny for future performance. Investors may view these mixed results as a cautious sign, keeping in mind potential upside from its strong growth model rating.

Stocks: IONS